February 23, 2017Current Pharmaceutical Design
Platelet Function Testing: A Role for Personalised Therapy in Coronary Disease
Key result
PFT-guided antiplatelet therapy shows no benefit for clinical outcomes in CAD.
Why the study?
Does individualized antiplatelet therapy guided by platelet function tests improve outcomes in patients with ACS or undergoing PCI?
Population
Patients with acute coronary syndrome (ACS) or those undergoing percutaneous coronary intervention (PCI)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Does not support routine platelet function testing to guide antiplatelet therapy in ACS/PCI; leaves open whether refined strategies benefit specific subgroups.
Structured PICO
Does individualized antiplatelet therapy guided by platelet function tests improve outcomes in patients with ACS or undergoing PCI?
P
Population
Patients with acute coronary syndrome (ACS) or those undergoing percutaneous coronary intervention (PCI)
I
Intervention
Platelet function tests (PFTs) to guide individualized antiplatelet therapy
O
Outcome
Thrombotic and bleeding events
Routine use of platelet function testing to guide individualized antiplatelet therapy is not currently supported by evidence to improve clinical outcomes.
Limitations
- Inherent limitations of the studies utilizing PFTs
- Important limitations to the relevance of currently available PFTs to the in vivo situation
- Inherent limitations of studies utilizing PFTs
- Lack of relevance of currently available PFTs to the in vivo situation
Cite This Study
Farag et al. (2017) conducted a review in Coronary Disease. Platelet function tests (PFTs) to guide individualized antiplatelet therapy was evaluated. Altering antiplatelet treatment based on platelet function tests has not been shown to influence clinical outcomes in patients with coronary disease.